Ann: iPPS Increases Cartilage Thickness in Phase 2 Trial, page-56

"anyone care to explain if there is anyone other cartilage enhancing medicine out there ?"

Not going to be a popular question during this positive news. Do your research and the main competition comes from stem cells, autologous treatments are already available and induced pluripotent (off-the-shelf), leading the approaches in which both ironically originate from two Australian companies. Autologous are in market but practically no one knows of them and off the shelf still at stage 3 trial stage not that different to PAR in agenda. Competition not really a risk at this very early point.

Its a massive market anyway that will accommodate $billions in all three approaches without even touching 5% of sufferers:

"The pooled global prevalence of knee OA was 16⋅0% (95% CI, 14⋅3%-17⋅8%) in individuals aged 15 and over and was 22⋅9% (95% CI, 19⋅8%-26⋅1%) in individuals aged 40 and over."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704420/

Its a ways to go, but the size of PAR's total addressable market is shudderingly huge.....this stock has been stupidly oversold in the great 'capital cost' sell off of non-FCF companies despite its massive potential forward earnings - even with a healthy risk probability applied.